RPA Study: Assessment of Nephrologist Practices in Managing Mineral Bone Disease in Patients with Advanced Chronic Kidney Disease
RPA is launching a new research project focused on the real-world management of mineral bone disease (MBD) in patients with advanced chronic kidney disease (CKD) and is looking for 10 nephrology practices to participate. Practices will abstract chart data and participate in phone interviews.
RPA will use a newly developed RPA Kidney Quality Improvement Module within the RPA Registry platform to gather information and data to achieve the following objectives:
Objective 1: To describe the real-world clinical management of MBD among patients with Stage 4-5 CKD in nephrology practices in the United States.
Objective 2: To characterize nephrologists’ perceptions about the clinical management of MBD in patients with Stage 4-5 CKD
Practices must have at least 10 nephrology providers.
Practices must identify a site champion to serve as study coordinator who will engage regularly with RPA and a clinical lead to serve as principle investigator. Practices will also identify a data abstractor and data validator.
Practices must commit to having at least 5 nephrologists participate in structured phone interviews.
Practices must have the ability to run historical reports from their EHRs to identify patients with a PTH of ≥110 pg/ml or patients prescribed a calcimimetic in 2019.
Practices must enter into a study contract and participate in the online training session.
Practices do not need to be current subscribers of the RPA Kidney Quality Improvement Registry.
Compensation and Time Commitment
Participating practices will receive a stipend of $5000 for their participation.
Chart abstraction is expected to take place between October – December 2020.
A minimal of 40 charts will abstracted by each practice
Chart abstraction is expected to take 2-4 hours per week.
Structured interviews are expected to be scheduled between October – December 2020.
Interviews will take approximately 30 minutes per nephrologist.
The project is chaired by former RPA Board member and Registry Workgroup Chair, Adam Weinstein, MD and is directed and overseen by a project faculty advisory group comprised of nephrologists, advanced practitioners, practice administrators and patients. The research study is supported by a grant from Amgen, Inc.
To express your interest in participating and receive more information click here. Please do by September 18, 2020. Please contact RPA Project Director, Amy Beckrich at firstname.lastname@example.org with any questions.